|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 369.19 USD | +1.52% |
|
-3.94% | +12.80% |
| 02-12 | Amgen Inc. Presents at Piper Sandler Virtual Novel Targets in Immunology Symposium, Feb-12-2026 05:00 PM | |
| 02-12 | European Commission approves Amgen's Uplizna® for generalized myasthenia gravis | RE |
Chart: Technical Analysis
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Bullish | Bullish | Bullish |
| Resistance | 384.32 | 384.32 | 384.32 |
| Spread/Res. | -3.94% | -3.94% | -3.94% |
| Spread/Supp. | +5.09% | +15.11% | +13.21% |
| Support | 351.32 | 320.72 | 326.1 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Equities
- AMGN Stock
- Charts Amgen Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition